G

Galmed Pharmaceuticals Ltd
D

GLMD

2.76000
USD
-0.07
(-2.47%)
Market Closed
Volume
260
EPS
-1
Div Yield
-
P/E
0
Market Cap
4,573,298
OverviewSignalsIdeasNews
Related Instruments
    A
    ACAD
    -0.240
    (-1.41%)
    16.790 USD
    A
    AMRN
    -0.01500
    (-2.88%)
    0.50510 USD
    B
    BGNE
    -4.220
    (-2.18%)
    189.320 USD
    C
    CTMX
    -0.08670
    (-8.67%)
    0.91330 USD
    E
    EGRX
    0
    (0%)
    0.000000 USD
    F
    FGEN
    -0.03530
    (-9.54%)
    0.33460 USD
    J
    JAZZ
    -2.620
    (-2.11%)
    121.660 USD
    JNJ
    JNJ
    2.140
    (1.41%)
    155.14 USD
    L
    LIVN
    -0.200
    (-0.38%)
    52.100 USD
    M
    MYOV
    0
    (0%)
    0.000000 USD
    N
    NBRV
    0.04000
    (2.84%)
    1.45000 USD
    R
    RIGL
    -3.530
    (-12.78%)
    24.100 USD
    S
    SSNC
    -0.810
    (-1.09%)
    73.410 USD
    X
    XENE
    -1.920
    (-4.60%)
    39.850 USD
    X
    XNCR
    -0.420
    (-1.79%)
    23.090 USD
    More
News

Title: Galmed Pharmaceuticals Ltd

Sector: Healthcare
Industry: Biotechnology
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIaclinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.